complementary dna (cdna) microarray system (MicroMax Inc)
90
Structured Review
MicroMax Inc
complementary dna (cdna) microarray system
Complementary Dna (Cdna) Microarray System, supplied by MicroMax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complementary+dna+(cdna)+microarray/cdna+microarray+system/pmc08246632-63-4-3
Average 90 stars, based on 1 article reviews
Complementary Dna (Cdna) Microarray System, supplied by MicroMax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complementary+dna+(cdna)+microarray/cdna+microarray+system/pmc08246632-63-4-3
Average 90 stars, based on 1 article reviews
complementary dna (cdna) microarray system - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Microarray:Article Title: Osteopontin as a potential diagnostic biomarker for ovarian cancer. Article Snippet: .. Previously, we described the Article Title: The regulation and role of osteopontin in malignant transformation and cancer. Article Snippet: Osteopontin (OPN) is a predominantly secreted extracellular matrix glycophosphoprotein which binds to alpha v-containing integrins and has an important role in malignant cell attachment and invasion.. High OPN expression in the primary tumor is associated with early metastasis and poor outcome in human breast and other cancers.. Forced OPN overexpression in benign cells may induce neoplastic-like cell behaviour including increased attachment and invasion in vitro as well as the ability to metastasize in vivo. Article Title: Genetically modified Article Snippet: These polystyrene flat-bottomed plates have black-pigmented, opaque walls to prevent well-to-well crosstalk and are optically clear for the passage of laser light.. Plate bottoms are 60% thinner than conventional polystyrene plates, resulting in lower background fluorescence.. Each plate has a total well volume of 360 ml. Article Title: Proteomic analysis of human prostate cancer. Article Snippet: Mamoun Ahram, Carolyn J.M.. Best, Michael J. Flaig, John W. Gillespie, Isabel M. Leiva, Rodrigo F. Chuaqui, Ge Zhou, Hungjun Shu, Paul H. Duray, W. Marston Linehan, Mark Raffeld, David K. Ornstein, Yingming Zhao, Emanuel F. Petricoin, III, and Michael R. Emmert-Buck* Pathogenetics Unit, Laboratory of Pathology and Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Science Applications International Corporation, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Department of Biochemistry, The University of Texas, Southwestern Medical Center, Dallas, Texas Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Department of Urology, University of North Carolina, Chapel Hill, North Carolina Tissue Proteomics Unit, Center for Biologics, Evaluation, and Research, Federal Drug Administration, Bethesda, Maryland other:Article Title: Evaluation of local and circulating osteopontin in malignant and benign primary bone tumors Article Snippet: Furthermore, using the Article Title: A Comparison of Gene Expression Profiles between Glucocorticoid Responder and Non-Responder Bovine Trabecular Meshwork Cells Using RNA Sequencing Article Snippet: Article Title: Possible sources of dye-related signal correlation bias in two-color DNA microarray assays. Article Snippet: DNA microarray analyses commonly use two spectrally distinct Xuorescent labels to simultaneously compare diVerent mRNA pools.. Signal correlation bias currently limits accepted resolution to twofold changes in gene expression.. This bias was investigated by (i) examining Xuorescence and absorption spectra and changes in relative Xuorescence of DNAs labeled with the Cy3, Cy5, Alexa Fluor 555, and Alexa Fluor 647 dyes and by (ii) using homotypic hybridization assays to compare the Cy dye pair with the Alexa Fluor dye pair. Biomarker Discovery:Article Title: The regulation and role of osteopontin in malignant transformation and cancer. Article Snippet: Osteopontin (OPN) is a predominantly secreted extracellular matrix glycophosphoprotein which binds to alpha v-containing integrins and has an important role in malignant cell attachment and invasion.. High OPN expression in the primary tumor is associated with early metastasis and poor outcome in human breast and other cancers.. Forced OPN overexpression in benign cells may induce neoplastic-like cell behaviour including increased attachment and invasion in vitro as well as the ability to metastasize in vivo. Fluorescence:Article Title: Proteomic analysis of human prostate cancer. Article Snippet: Mamoun Ahram, Carolyn J.M.. Best, Michael J. Flaig, John W. Gillespie, Isabel M. Leiva, Rodrigo F. Chuaqui, Ge Zhou, Hungjun Shu, Paul H. Duray, W. Marston Linehan, Mark Raffeld, David K. Ornstein, Yingming Zhao, Emanuel F. Petricoin, III, and Michael R. Emmert-Buck* Pathogenetics Unit, Laboratory of Pathology and Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Science Applications International Corporation, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Department of Biochemistry, The University of Texas, Southwestern Medical Center, Dallas, Texas Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Department of Urology, University of North Carolina, Chapel Hill, North Carolina Tissue Proteomics Unit, Center for Biologics, Evaluation, and Research, Federal Drug Administration, Bethesda, Maryland Generated:Article Title: Proteomic analysis of human prostate cancer. Article Snippet: Mamoun Ahram, Carolyn J.M.. Best, Michael J. Flaig, John W. Gillespie, Isabel M. Leiva, Rodrigo F. Chuaqui, Ge Zhou, Hungjun Shu, Paul H. Duray, W. Marston Linehan, Mark Raffeld, David K. Ornstein, Yingming Zhao, Emanuel F. Petricoin, III, and Michael R. Emmert-Buck* Pathogenetics Unit, Laboratory of Pathology and Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Science Applications International Corporation, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Department of Biochemistry, The University of Texas, Southwestern Medical Center, Dallas, Texas Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Department of Urology, University of North Carolina, Chapel Hill, North Carolina Tissue Proteomics Unit, Center for Biologics, Evaluation, and Research, Federal Drug Administration, Bethesda, Maryland |